Vita Life Sciences (VLS) H2 2024 earnings summary

Executive summary

• Revenue reached a record $79.5m, up 8.3% year-over-year, driven by new retail partners and expanded product consumption.

• Net profit after tax declined 3.3% to $8.8m, with EPS down 5.6% to 15.97 cents per share compared to the prior year.

• The company remains debt free, with net assets increasing 21% to $52.3m and cash holdings of $28.6m.

• Fully franked dividends for FY2024 total 10.0 cents per share, marking the 15th consecutive year of dividend payments.

Financial highlights

• EBIT was $12.4m, down 0.1% year-over-year; EBITDA was $12.4m.

• Gross profit rose to $47.2m from $42.4m, with gross margin improving year-over-year.

• Operating cash flow before interest and tax was $6.2m, down from $13.0m in the prior year.

• Final dividend of 6.5 cents per share declared, with a 63% payout ratio to profit after tax.

Outlook and guidance

• Trading conditions remain positive heading into 2025, with continued focus on brand growth and market penetration.

• No formal quantitative guidance provided, but management expects sustained revenue growth and resilience.